In order to continue supporting customers and partners as best as possible, at ZEISS we are doing everything we can to protect our employees’ health and safety as well as maintain production in our plants and ensure our service operations.
In January, ZEISS set up a dedicated task force. We are closely assessing the latest developments together with government agencies and healthcare authorities on an ongoing basis. Decisions are made daily regarding the most sensible measures for ZEISS to take.
Of course, we will continue to be available for our customers as best we can. Some employees in individual areas are currently working remotely but can still be reached at their usual phone numbers and email addresses.
However, should our customers experience any disruptions in service at some of our sites and sales offices, we can also be contacted on these numbers.
All over the world, the company and its employees are joining the fight against the spread and consequences of the coronavirus pandemic. Read more
16 December 2021
The Carl Zeiss AG shareholders' meeting has appointed Dr. Michael Bolle the new Supervisory Board member to represent the sole shareholder the Carl Zeiss Foundation. He will be elected Chairman of the Supervisory Board of Carl Zeiss AG in January 2022.
15 December 2021
The ZEISS Group ended fiscal year 2020/21 (end of reporting period: 30 September 2021) on an excellent note: its revenue rose by 20% to 7.529 billion euros (previous year: 6.297 billion euros). Earnings before interest and tax (EBIT) also achieved a new high, reaching 1.479 billion euros (prior year: 922 million euros).
10 December 2021
Carl Zeiss Meditec generated revenue of approximately €1,647m in fiscal year 2020/21 (prior year: €1,336m), corresponding to growth of +23.3% (adjusted for currency effects: +26.5%). Orders received increased even more significantly to approximately €1,731m (+29.1%, adjusted for currency effects: +32.6%).